Thymosin Alpha-1
Approved (multiple countries)Thymosin Alpha-1
- Category
- Immune & Inflammatory
- Aliases
- Tα1, Zadaxin, Thymalfasin
- Administration
- Subcutaneous injection
Research and regulatory
Development stage
Approved in 35+ countries for hepatitis B, hepatitis C, and cancer adjunct therapy (Zadaxin/thymalfasin).
Legal and regulatory
Approved pharmaceutical in 35+ countries; FDA orphan drug designation (1991); not FDA-approved for marketing in the US.
Side effects
Mild injection site reactions; excellent safety profile